{"id":"anagliptin","rwe":[{"pmid":"41641475","year":"2026","title":"Safety of anagliptin/metformin combination tablets evaluated by non-inferiority between pre- and post-serum lactic acid levels in Japanese patients with type 2 diabetes and moderate renal impairment (AMELIO STUDY).","finding":"","journal":"Journal of diabetes investigation","studyType":"Clinical Study"},{"pmid":"41631452","year":"2026","title":"Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice.","finding":"","journal":"Journal of diabetes investigation","studyType":"Clinical Study"},{"pmid":"41088738","year":"2025","title":"Gastric Emptying Delay with Pre-Meal Administration of Metformin and Anagliptin in Type 2 Diabetes: Effects on Postprandial Glucose and Triglyceride Levels in a Two-Case Report.","finding":"","journal":"The American journal of case reports","studyType":"Clinical Study"},{"pmid":"40557734","year":"2025","title":"EffiCacy and safety of ANagliptin when added to iNsulin and metformin therapy in patients with uncontrolled type 2 diAbetes; randomized, placebo-controlled, double-blind, multicentre trial (CANNA study).","finding":"","journal":"Diabetes, obesity & metabolism","studyType":"Clinical Study"},{"pmid":"40527218","year":"2025","title":"Pyrimidine derivatives as multifaceted antidiabetic agents: A comprehensive review of structure-activity relationships, mechanisms, and clinical potential.","finding":"","journal":"European journal of medicinal chemistry","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Dipeptidyl peptidase 4","category":"target"},{"label":"DPP4","category":"gene"},{"label":"DPP9","category":"gene"},{"label":"DPP8","category":"gene"},{"label":"Active","category":"status"},{"label":"Diabetes mellitus type 2","category":"indication"},{"label":"Dipeptidyl-Peptidase IV Inhibitors","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Hypoglycemic Agents","category":"pharmacology"},{"label":"Protease Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T15:50:24.986755","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ANAGLIPTIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:31:48.653198+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:31:54.313858+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ANAGLIPTIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:31:55.019238+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Dipeptidyl peptidase IV inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:31:56.067220+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1929396/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:31:55.718655+00:00"}},"allNames":"suiny","offLabel":[],"synonyms":["anagliptin HCl","anagliptin","beskoa","anagliptin hydrochloride","suiny"],"timeline":[{"date":"2012-09-28","type":"positive","source":"DrugCentral","milestone":"PMDA approval"}],"brandName":"Suiny","ecosystem":[{"indication":"Diabetes mellitus type 2","otherDrugs":[{"name":"acarbose","slug":"acarbose","company":"Bayer Hlthcare"},{"name":"acetohexamide","slug":"acetohexamide","company":"Lilly"},{"name":"albiglutide","slug":"albiglutide","company":"Glaxosmithkline Llc"},{"name":"alogliptin","slug":"alogliptin","company":"Takeda Pharms Usa"}],"globalPrevalence":537000000}],"mechanism":{"target":"Dipeptidyl peptidase 4","targets":[{"gene":"DPP4","source":"DrugCentral","target":"Dipeptidyl peptidase 4","protein":"Dipeptidyl peptidase 4","isPrimary":true,"activityType":"IC50","activityValue":8.42},{"gene":"DPP9","source":"DrugCentral","target":"Dipeptidyl peptidase 9","protein":"Dipeptidyl peptidase 9"},{"gene":"DPP8","source":"DrugCentral","target":"Dipeptidyl peptidase 8","protein":"Dipeptidyl peptidase 8"},{"gene":"FAP","source":"DrugCentral","target":"Prolyl endopeptidase FAP","protein":"Prolyl endopeptidase FAP"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Suiny inhibits the Dipeptidyl peptidase 4 (DPP-4) enzyme, preventing the breakdown of incretin hormones such as GLP-1 and GIP, which stimulate insulin release and decrease glucagon levels, ultimately lowering blood glucose levels."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4896","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ANAGLIPTIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ANAGLIPTIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:43:35.507216","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:31:57.344811+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"linagliptin","drugSlug":"linagliptin","fdaApproval":"2011-05-02","patentExpiry":"Sep 5, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"sitagliptin","drugSlug":"sitagliptin","fdaApproval":"2006-10-16","patentExpiry":"Feb 25, 2035","patentStatus":"Patent protected","relationship":"same-target"}],"genericName":"anagliptin","indications":{"approved":[{"name":"Diabetes mellitus type 2","source":"DrugCentral","snomedId":44054006,"regulator":"FDA","usPrevalence":37300000,"globalPrevalence":537000000,"prevalenceMethod":"curated","prevalenceSource":"IDF Diabetes Atlas, 2024"}],"offLabel":[],"pipeline":[]},"_fixedFields":["primaryTarget","pubmed(118)"],"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"linagliptin","brandName":"linagliptin","genericName":"linagliptin","approvalYear":"2011","relationship":"same-target"},{"drugId":"sitagliptin","brandName":"sitagliptin","genericName":"sitagliptin","approvalYear":"2006","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT07442006","phase":"PHASE4","title":"Glycemic Variability of Combination Therapies in T2DM","status":"RECRUITING","sponsor":"JW Pharmaceutical","startDate":"2025-10-29","conditions":["Type 2 Diabetes Mellitus (T2DM)"],"enrollment":178,"completionDate":"2027-03-31"},{"nctId":"NCT03014479","phase":"PHASE4","title":"Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-02-18","conditions":["Type 2 Diabetes"],"enrollment":219,"completionDate":"2017-10-21"},{"nctId":"NCT04267601","phase":"","title":"Korean Observational Study to Evaluate the Efficacy and Safety of Anagliptin Switching From Other DPP4is in type2 DM","status":"UNKNOWN","sponsor":"JW Pharmaceutical","startDate":"2017-07-06","conditions":["Type 2 Diabetes Mellitus"],"enrollment":2448,"completionDate":"2021-09-30"},{"nctId":"NCT04810507","phase":"PHASE4","title":"MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2018-11-09","conditions":["Type 2 Diabetes"],"enrollment":89,"completionDate":"2021-01-05"},{"nctId":"NCT02330406","phase":"PHASE4","title":"Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial","status":"COMPLETED","sponsor":"Institute for Clinical Effectiveness, Japan","startDate":"2015-04","conditions":["Dipeptidyl-Peptidase 4 Inhibitors","LDL Cholesterol","Glycosylated Hemoglobin","Diabetes Mellitus","Coronary Disease"],"enrollment":353,"completionDate":"2019-03"},{"nctId":"NCT02312427","phase":"PHASE4","title":"DPP-4 Inhibitor and Serum BNP Level of Diabetic Patients With Congestive Heart Failure","status":"COMPLETED","sponsor":"Mitsui Memorial Hospital","startDate":"2015-01","conditions":["Heart Failure","Diabetes Mellitus"],"enrollment":10,"completionDate":"2016-03"},{"nctId":"NCT02528019","phase":"PHASE4","title":"Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors","status":"UNKNOWN","sponsor":"Kurume University","startDate":"2015-08","conditions":["Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications"],"enrollment":100,"completionDate":"2018-08"},{"nctId":"NCT01529541","phase":"PHASE3","title":"Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2011-05","conditions":["Type 2 Diabetes Mellitus"],"enrollment":200,"completionDate":"2013-10"},{"nctId":"NCT01529528","phase":"PHASE3","title":"A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2011-05","conditions":["Type 2 Diabetes Mellitus"],"enrollment":117,"completionDate":"2012-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"K726J96838","CHEBI":"CHEBI:136043","INN_ID":"9246","UMLSCUI":"C3272640","chemblId":"CHEMBL1929396","ChEMBL_ID":"CHEMBL1929396","KEGG_DRUG":"D09780","DRUGBANK_ID":"DB12417","PDB_CHEM_ID":" SKK","PUBCHEM_CID":"44513473","IUPHAR_LIGAND_ID":"11582","MESH_SUPPLEMENTAL_RECORD_UI":"C583175"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","fractionUnbound":"0.77%"},"publicationCount":118,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb 5","pmid":"41641475","title":"Safety of anagliptin/metformin combination tablets evaluated by non-inferiority between pre- and post-serum lactic acid levels in Japanese patients with type 2 diabetes and moderate renal impairment (AMELIO STUDY).","journal":"Journal of diabetes investigation"},{"date":"2026 Feb 3","pmid":"41631452","title":"Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice.","journal":"Journal of diabetes investigation"},{"date":"2025 Oct 15","pmid":"41088738","title":"Gastric Emptying Delay with Pre-Meal Administration of Metformin and Anagliptin in Type 2 Diabetes: Effects on Postprandial Glucose and Triglyceride Levels in a Two-Case Report.","journal":"The American journal of case reports"},{"date":"2025 Sep","pmid":"40557734","title":"EffiCacy and safety of ANagliptin when added to iNsulin and metformin therapy in patients with uncontrolled type 2 diAbetes; randomized, placebo-controlled, double-blind, multicentre trial (CANNA study).","journal":"Diabetes, obesity & metabolism"},{"date":"2025 Oct 15","pmid":"40527218","title":"Pyrimidine derivatives as multifaceted antidiabetic agents: A comprehensive review of structure-activity relationships, mechanisms, and clinical potential.","journal":"European journal of medicinal chemistry"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"2012","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:31:57.344811+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}